🧠 Food for thought

Implications, context, and why it matters.

Hong Kong’s IPO market is seeing rising AI-related activity

• A possible METiS IPO fits a broader run-up. Hong Kong IPOs raised US$3.7 billion year-to-date as of 23 January 2026, up from US$0.8 billion across all of January 2025 1. HKEX (Hong Kong Exchanges and Clearing, which runs the Hong Kong Stock Exchange) attributed part of the 2026 jump to AI listings in December and January 1.
• Insilico Medicine, an AI drug discovery firm, listed on the Hong Kong Stock Exchange on Dec. 30, 2025. It raised HKD 2.277 billion (about US$300 million) and said demand far exceeded the shares offered. The company also called it Hong Kong’s largest biotech IPO of 2025 by fundraising size 2.
• Big-ticket biopharma deals have also increased. DealForma (a biotech deal-tracking database) figures cited by DealForma CEO Chris Dokomajilar put 2025 at 18 big pharma in-licensing and asset purchase deals from Chinese companies with $50 million-plus upfronts. Those deals totaled $57.3 billion in value and $3.9 billion in upfront cash and equity 3.

China’s AI drug discovery efforts signal a shift in how drug R&D is being scaled

• State support is backing an AI-plus-automation approach. Insilico Medicine says it built “Life Star 1,” which it described as the industry’s first fully automated biology laboratory. It aims to feed data into its AI platform to improve the system 2.
• Scale carries into clinical work. One industry analysis puts China at about 7,700 clinical trials in 2025 versus roughly 6,200 in the U.S. The same analysis says regulatory reforms cut China’s first-in-human approval timeline to around 87 days 4.
• Faster cycles are pushing China toward higher-value drug innovation. One industry analysis estimates Chinese biotechs file nearly 70% of global AI-driven drug discovery patents. A separate report cited in DealForma’s figures puts China at about 32% of global out-licensing deal value 4, 5. Executives at the Asian Financial Forum (a Hong Kong business and finance conference) also raised China as an early approval market for fully AI-designed drugs, and Merck China president Marc Horn said 2026 could bring end-to-end AI-designed compounds into regulatory pipelines 3.